학술논문
Safety and effectiveness of isavuconazole in real-life non-neutropenic patients
Document Type
article
Author
Patricia Monzó-Gallo; Carlos Lopera; Ana M Badía-Tejero; Marina Machado; Julio García-Rodríguez; Pablo Vidal-Cortés; Esperanza Merino; Jorge Calderón; Jesús Fortún; Zaira R. Palacios-Baena; Javier Pemán; Joan Roig Sanchis; Manuela Aguilar-Guisado; Carlota Gudiol; Juan C Ramos; Isabel Sánchez-Romero; Pilar Martin-Davila; Luis E. López-Cortés; Miguel Salavert; Isabel Ruiz-Camps; Mariana Chumbita; Tommaso Francesco Aiello; Olivier Peyrony; Pedro Puerta-Alcalde; Alex Soriano; Francesc Marco; Carolina Garcia-Vidal
Source
International Journal of Infectious Diseases, Vol 144, Iss , Pp 107070- (2024)
Subject
Language
English
ISSN
1201-9712
27134717
27134717
Abstract
ABSTRACT: Objectives: Information is scarce on clinical experiences with non-neutropenic patients with invasive fungal infection (IFI) receiving isavuconazole. We aimed to report the safety and effectiveness of this drug as a first-line treatment or rescue in real life. Methods: A retrospective, observational multicentric study of non-neutropenic patients who received isavuconazole as an IFI treatment at 12 different university hospitals (January 2018-2022). All patients met criteria for proven, probable or possible IFI according to EORTC-MSG. Results: A total of 238 IFIs were treated with isavuconazole during the study period. Combination therapy was administered in 27.7% of cases. The primary IFI was aspergillosis (217, 91.2%). Other IFIs treated with isavuconazole were candidemia (n = 10), mucormycosis (n = 8), histoplasmosis (n = 2), cryptococcosis (n = 2), and others (n = 4). Median time of isavuconazole treatment was 29 days. Only 5.9% (n = 14) of cases developed toxicity, mainly hepatic-related (10 patients, 4.2%). Nine patients (3.8%) had treatment withdrawn. Successful clinical response at 12 weeks was documented in 50.5% of patients. Conclusion: Isavuconazole is an adequate treatment for non-neutropenic patients with IFIs. Toxicity rates were low and its effectiveness was comparable to other antifungal therapies previously reported.